Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation

A pulmonary fibrosis and thymosin technology, applied in the field of medicine, can solve the problems of lack of practical and effective treatment methods for idiopathic pulmonary fibrosis, increased mortality, and aggravation of the disease, so as to correct the imbalance of immune function, reduce the incidence of infection, The effect of improving the quality of life

Inactive Publication Date: 2013-03-20
SHANGHAI PULMONARY HOSPITAL
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis formulated in March 2011 disclosed that the incidence of IPF has shown a clear increase trend, and the mortality rate has increased significantly in the past 20 years, and the mortality rate is higher than that of some cancers. There is still no effective treatment for chronic pulmonary fibrosis
One of the reasons is: after using hormones, as time goes on, the side effects of hormones become more and more prominent, and various pathogen infections often occur due to severe impairment of immune function, which aggravates the disease and leads to death. Patients on hormones live shorter
More studies have found that IPF patients themselves are more likely to be aggravated by various pathogenic infections than normal people due to their own immune deficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation
  • Uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation
  • Uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1. Establishment, grouping and specimen processing of animal models:

[0048] All rats were randomly divided into five groups:

[0049] (1) Blank control group (NS group, 0.3ml of normal saline was injected into the trachea, and 0.16ml of normal saline was injected into the abdominal cavity every day);

[0050] (2) Model control group (BLM group, 5 mg / kg bleomycin was injected into the trachea to make a rat model of pulmonary fibrosis, and 0.16 ml of normal saline was injected into the abdominal cavity every day);

[0051] (3) Dexamethasone intervention group (BLM+DXM group, daily intraperitoneal injection of dexamethasone 3 mg / kg after making pulmonary fibrosis model);

[0052] (4) Thymosin α1 intervention group (BLM+Tα1 group, daily intraperitoneal injection of 0.16ml of normal saline after making pulmonary fibrosis model, subcutaneous injection of thymosin α1 0.18mg / kg twice a week);

[0053] (5) Dexamethasone+thymosin α1 intervention group (BLM+DXM+Tα1 group, intr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the technical field of medicine, and relates to new medicinal uses of thymopeptide alpha1, specifically to uses of thymopeptide alpha1 in pulmonary fibrosis drug preparation. Based on disadvantages of extremely poor prognosis, no effective treatment method, extremely high death rate and the like in idiopathic pulmonary fibrosis treatment by using the existing drugs, a strategy for targeted Th1 type reaction increase or Th2 type reaction inhibition is adopted, thymopeptide alpha1 is adopted as an immune modulator to increase the Th1 type immune reaction and other immune modulation effects, and animal experiment results show that immune disbalance of the pulmonary fibrosis body can be corrected with the thymopeptide alpha1, infection incidence rate can be significantly reduced, and death rate can be reduced, such that the thymopeptide alpha1 can further be used for preparation of pulmonary fibrosis drugs. According to the present invention, under the status of lack of effective pulmonary fibrosis disease treatment drugs, important clinical values are provided, and reliable experimental basis is provided for wide clinical applications.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a new medicinal application of thymosin α1, in particular to the application of thymosin α1 (Ridaxian) in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] So far, the cause of idiopathic pulmonary fibrosis (IPF) is unknown, the pathogenesis is unclear, the prognosis is poor, the 5-year survival rate is less than 50%, and the median survival time after diagnosis is only 2-3 years. The guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis formulated in March 2011 disclosed that the incidence of IPF has shown a clear increase trend, and the mortality rate has increased significantly in the past 20 years, and the mortality rate is higher than that of some cancers. There is still no effective treatment for pulmonary fibrosis. [0003] Adrenal glucocorticoid (referred to as: hormone) has been the main means of IPF treatme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/22A61P11/00
Inventor 李惠萍范峰
Owner SHANGHAI PULMONARY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com